No Data
No Data
No Data
No Data
No Data
Surmodics Is Maintained at Outperform by Barrington Research
Surmodics Is Maintained at Outperform by Barrington Research
Dow Jones02:35
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Zhitong Finance02:30
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating.
MT NewswiresMay 2 21:36
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
TipRanksMay 2 21:20
The 28% Return This Week Takes Surmodics' (NASDAQ:SRDX) Shareholders One-year Gains to 45%
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. For example, the Surmodics, I
Simply Wall StMay 2 19:52
Earnings Call Summary | SurModics(SRDX.US) Q2 2024 Earnings Conference
The following is a summary of the Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript:Financial Performance:Surmodics reported Q2 revenue growth of 18% to $32 million, exceeding expectations.Medic
Futu NewsMay 2 11:40 · Conference Call
No Data
No Data